301 Antihypertensive Medications and Risk of Keratinocyte Carcinoma

F. M. Shaw,W. Li,M. A. Weinstock
DOI: https://doi.org/10.1016/j.jid.2018.03.307
IF: 7.59
2018-01-01
Journal of Investigative Dermatology
Abstract:Keratinocyte carcinoma, which includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a highly prevalent cancer in the population at large and accounts for up to three-quarters of all cancer diagnoses. It is hypothesized that certain antihypertensive medications may affect the risk of BCC and SCC, but this relationship remains inconclusive. We addressed this issue by using data from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, a randomized controlled multicenter trial that looked at the effects of topical 5-fluorouracil on BCC and SCC development. The trial followed 932 veterans at high risk for skin cancer for an average time of 2.7 years at 12 Veterans Affairs Medical Centers across the country. A total of 359 participants (39%) developed at least one histopathologically confirmed keratinocyte carcinoma over the course of the trial. This data on skin cancer development was then combined with Veterans Health Administration pharmacy records to evaluate the effects of various antihypertensive medications on keratinocyte carcinoma development. Antihypertensive medications had no overall association with BCC or SCC risk during the trial, nor did any of the four major subcategories of antihypertensive medications (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta blockers, calcium channel blockers, or diuretics). However, there was an increased risk of SCC (but not BCC) associated with hydrochlorothiazide use (hazard ratio, 1.53; 95% CI, 1.04 2.24; p = 0.031). We failed to replicate our prior observation of a reduced risk of keratinocyte carcinoma associated with the use of angiotensin-converting enzyme inhibitor drugs. Our findings show a distinct effect of hydrochlorothiazide on SCC risk, perhaps related to its associated photosensitivity, but we were otherwise unable to document any association between antihypertensive medications and keratinocyte carcinoma.
What problem does this paper attempt to address?